{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-006629","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.672084+00:00","generated_at":"2026-05-15T22:17:19.878255+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Pulse Biosciences updates investor deck with nPulse catheter development, cites 'unprecedented' EU feasibility data","bullets":["Updated investor presentation posted on website includes summary financial info and product development update.","Next-generation nPulse cardiac catheter under development is highlighted.","Company strengthening focus on EP cardio ablation following 'unprecedented' EU feasibility study outcomes.","Presentation to be used in meetings with investors and analysts."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-006629","json":"https://secwatch.observer/filing/0001437749-26-006629.json","markdown":"https://secwatch.observer/filing/0001437749-26-006629.md","text":"https://secwatch.observer/filing/0001437749-26-006629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926006629/0001437749-26-006629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926006629/plse20260302_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:17:19.878255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}